Core Insights - Conavi Medical Corp. announced financial results for Q1 2025, reporting a revenue of approximately CAD 58,000, a significant decrease from CAD 589,000 in the same period last year [8][9] - The company raised CAD 20 million in financing to support the development and commercial launch of the next-generation Novasight Hybrid system, with U.S. institutional investors participating [2][5] - New U.S. intracoronary imaging guidelines validate the clinical utility of the Novasight system, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [5][6] Financial Performance - For Q2 2025, operating expenses were approximately CAD 5.6 million, down from CAD 6.0 million in Q2 2024, primarily due to reduced research and development costs [9] - The net loss for Q2 2025 was approximately CAD 3.1 million, or CAD 0.07 per share, compared to a net loss of CAD 7.1 million, or CAD 1.15 per share, in Q2 2024 [10] - As of March 31, 2025, cash and cash equivalents were approximately CAD 1.0 million, an increase from CAD 0.4 million as of September 30, 2024 [11] Product Development and Regulatory Milestones - The company is on track for a U.S. FDA 510(k) submission for the next-generation Novasight system in Q3 2025 [3][5] - Expected completion of usability and system validation with key opinion leaders is set for Q4 2025 [4] - The planned commercial launch of the Novasight Hybrid system is anticipated in H1 2026 [5][6] Market Position and Strategy - The recent financing and new medical guidelines position Conavi Medical to unlock substantial shareholder value [2][5] - The company aims to improve investor transparency and visibility through uplisting to the OTCQB [6] - Upcoming publications in academic journals are expected to drive awareness of the Novasight system [7]